Lara Sullivan, Pyxis Oncology CEO

An­oth­er three biotechs are set to de­but on Nas­daq as com­bined in­dus­try raise tops $14B

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

De­spite an IPO slow­down in the third quar­ter, it’s be­com­ing ap­par­ent that Q4 will again see an ac­tive biotech mar­ket bare­ly a week in­to Oc­to­ber.

Two more com­pa­nies priced their ini­tial pub­lic of­fer­ings late Thurs­day night in Pyx­is On­col­o­gy and Iso­Plex­is. Pyx­is led the way by launch­ing at $16 per share and with a $168 mil­lion raise, while Iso­Plex­is fol­lowed up with a $15 de­but and $125 mil­lion in IPO cash.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA